Under construction – not a live service
Sign in
Taking people in United KingdomPhase 2

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Key facts

Who runs it
Immunovant Sciences GmbH
Where
Cornwell, London, Merthyr Tydfil, Salford, and Surrey, United KingdomSee the 6 sitesAlso in 18 other countries, 162 sites
Status
Recruiting
Phase
Phase 2
People taking part
210 people, planned
Started
19 Jun 2025
Expected to end
May 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • IMVT-1402
  • Placebo
Record updated
30 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures
  • Male or female participants aged ≥ 18 years
  • Participants with diagnosis of GD who are hyperthyroid despite ATD treatment
  • Other, more specific inclusion criteria are defined in the protocol

Who cannot take part

  • Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy
  • Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk
  • Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation
  • Additional exclusion criteria are defined in the protocol

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United Kingdom

Also in 18 other countries, 162 sites

  • CornwellHospital not named in the registryTaking people
  • LondonHospital not named in the registryTaking people
  • LondonHospital not named in the registryTaking people
  • Merthyr TydfilHospital not named in the registryTaking people
  • SalfordHospital not named in the registryTaking people
  • SurreyHospital not named in the registryTaking people

About the trial

What the trial wants to find out

This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

The 3 groups in the trial

  • IMVT-1402 Dose 1Treatment being tested

    Treatment: IMVT-1402

  • IMVT-1402 Dose 2Treatment being tested

    Treatment: IMVT-1402

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Fit questions
Built from NCT07018323, who can take part
Record updated
30 October 2026